AHCO vs DXCM
AHCO: AdaptHealth delivers home medical equipment, supplies, and chronic disease management services directly to patients, focusing on sleep apnea, respiratory diseases, diabetes, and post-acute recovery. DXCM: Dexcom is a leader in continuous glucose monitoring (CGM) technology, providing essential real-time health data for diabetes management and metabolic health.
Side-by-side fundamentals
| Metric | AHCO | DXCM | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $10.88 | $71.43 | |
| Market cap as of 2026-07-23 | $1.5B | $28.8B | |
| P/E as of 2026-07-23 | n/a | 31.00 | |
| PEG as of 2026-07-23 | n/a | 1.26 | |
| Net margin as of 2026-07-23 | -2.4% | +19.3% | DXCM higher |
| Gross margin as of 2026-07-23 | +20.6% | +63.4% | DXCM higher |
| Operating margin as of 2026-07-23 | +2.2% | +21.4% | DXCM higher |
| ROE as of 2026-07-23 | -5.1% | +33.8% | DXCM higher |
| ROA as of 2026-07-23 | -1.8% | +13.4% | DXCM higher |
| Debt / equity as of 2026-07-23 | 1.24 | 0.44 | DXCM lower |
| Revenue growth (YoY) as of 2026-07-23 | +1.2% | +16.1% | DXCM higher |
| Revenue CAGR (3y) SEC XBRL | +3.0% | +17.0% | DXCM higher |
| Beta as of 2026-07-23 | 1.47 | 1.42 | |
| 1-year return as of 2026-07-22 close | +22.5% | -11.0% | AHCO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.